Q-omics provides the consensus-scored RN7SL552P profile across patient tissues and cancer cell-line models. RN7SL552P expression is associated with patient survival in 18 of 34 cancer types, with the highest sampling consensus in THYM. Among the 18 cancer types available for tumor–normal comparison, RN7SL552P is differentially expressed in 5, with the highest sampling consensus in CHOL. Additionally, RN7SL552P RNA expression shows 6,151 significant pathway-activity associations, with the highest sampling consensus in KIRC. Together, these results highlight THYM, CHOL, and KIRC as cancer lineages where RN7SL552P shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RN7SL552P — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RN7SL552P survival associations across molecular data types. RN7SL552P RNA expression shows survival associations in the most cancer types (18). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RN7SL552P RNA expression–survival associations across cancer types. High RN7SL552P expression shows unfavorable associations in THYM, BRCA, KIRP, LUSC and UCEC, but favorable associations in HNSC. The THYM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify THYM as the clearest survival context for RN7SL552P RNA expression.
This table summarizes RN7SL552P tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 5. The strongest signals are observed in CHOL for RNA.
This table ranks reproducible tumor–normal expression differences for RN7SL552P. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RN7SL552P shows lower tumor expression in KICH and READ and higher tumor expression in CHOL, BLCA and KIRP. The CHOL box plot shows higher RN7SL552P RNA expression in tumor versus normal tissue (log2 FC = +0.387, t-test p < 0.001).
This table shows molecular features associated with RN7SL552P in patient tissues and cancer cell lines. In patient samples, RN7SL552P shows the broadest associations at the RNA and protein expression levels, with KIRC recurring as the lineage with the largest associated feature set.
